| Parameters | All cases | MSS | MSI-H | p Value* |
| (n = 45) | (n = 31) | (n = 14) | ||
| n (%) | n (%) | n (%) | ||
| Gender (F) | 21 (47) | 11 (35) | 10 (71) | 0.05 |
| Mean age at surgery (SD) | 69.7 (1.5) | 68.8 (1.8) | 71.8 (2.8) | 0.40 |
| Right-sided tumour | 19 (42) | 9 (29) | 10 (71) | 0.01 |
| No or poor differentiation | 27 (60) | 20 (70) | 7 (50) | 0.21 |
| Mucous component | 4 (1) | 0 (0) | 4 (40) | 0.01 |
| Lymphocyte infiltration† | 14 (31) | 1 (3) | 13 (93) | 0.0001 |
| Tumour staging | ||||
| pT 1–2 | 4 (9) | 2 (6) | 2 (14) | |
| pT 3 | 27 (60) | 16 (52) | 11 (79) | |
| pT 4 | 14 (31) | 13 (42) | 1 (7) | 0.05 |
| N0 | 26 (58) | 15 (48) | 11 (79) | |
| N1–2 | 19 (42) | 16 (52) | 3 (21) | 0.10 |
| Synchronous metastasis | 22 (49) | 19 (61) | 3 (21) | 0.02 |
| Vascular emboli | 25 (56) | 20 (65) | 5 (36) | 0.03 |
| Perinervous infiltration | 7 (16) | 5 (16) | 2 (14) | 1 |
| Relapse within 36 months of follow-up | 10 (22) | 8 (26) | 2 (14) | 0.47‡ |
*p Value of Fisher exact test or Mann–Whitney test as appropriate. †Assessed by histopathology evaluation (yes = + to ++; no = 0 to +/−). ‡p Value of log-rank test for equality of survivor functions.
F, female, MSS, microsatellite stability; MSI-H, high-frequency microsatellite instability.